The Central government, amidst rising concerns over surrogate advertising and misleading awareness campaigns, directed regulators across states and Union Territories to tighten surveillance over the supply chain and promotion of GLP-1 weight-loss drugs.
The Minister of State for Health Anupriya Patel, in a written reply in the Rajya Sabha on Tuesday said glucagon-like peptide-1 (GLP-1) receptor agonists has been approved by the Central Drugs Standard Control Organisation (CDSCO) only for the treatment of Type 2 diabetes in adults and for chronic weight management in adults with specific medical conditions.